Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 167

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 167
---
 specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit, enroll and retain a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in or, once enrolled, continue with our studies for any reason, the timeline for conducting studies and obtaining regulatory approval of potential products may be delayed. 

The enrollment and retention of patients further depends on many factors, including:  

78

•the size of the patient population and process for identifying patients; 

•the eligibility criteria for the clinical trial in question; 

•the availability of an appropriate screening test, as necessary; 

•the perceived risks and benefits of the product candidate under study; 

•the efforts to facilitate timely enrollment in clinical trials; 

•the proximity and availability of clinical trial sites for prospective patients; 

•the design of the clinical trial; 

•our ability to recruit clinical trial investigators with the appropriate competencies and experience; 

•our ability to obtain and maintain patient consents; 

•reporting of the preliminary results of any of our clinical trials; and 

•the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion. 

In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current product candidates and any future product candidates, and this competition may reduce the number and types of patients available to us because some patients who might have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which may reduce the number of patients who are available for our clinical trials at such clinical trial sites. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials. 

If we experience delays in the completion of, or termination of, any clinical trial of our current product candidates and any future product candidates, the commercial prospects of our current product candidates